Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Non-Hodgkin 1

Interventions

Cyclophosphamide 15Rituximab 13Magnetic Resonance Spectroscopy 8obinutuzumab 7fludarabine phosphate 7fludarabine 7Specimen Handling 7Prednisone 6Biopsy 6polatuzumab vedotin 5ibrutinib 5X-Rays 5Whole-Body Irradiation 5Phantoms, Imaging 5Nuclear Medicine Department, Hospital 5Melphalan 5Lenalidomide 5Etoposide 5tocilizumab 4Mycophenolic Acid 4Doxorubicin 4Cyclosporine 4Busulfan 4venetoclax 3pembrolizumab 3glofitamab 3acalabrutinib 3Vincristine 3Tacrolimus 3Nivolumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, Non-Hodgkin × efineptakin alfa × 30 days × Clear all
NCT07052305 2026-05-13

NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleucel in Subjects With Relapsed/Refractory Large B-cell Lymphoma

Washington University School of Medicine

Phase 1 Recruiting
24 enrolled
Lymphoid

Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon âš¡